Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Non Operating Income: 2017-2025

Historic Non Operating Income for Puma Biotechnology (PBYI) over the last 8 years, with Sep 2025 value amounting to -$330,000.

  • Puma Biotechnology's Non Operating Income rose 77.57% to -$330,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.6 million, marking a year-over-year increase of 65.80%. This contributed to the annual value of -$6.9 million for FY2024, which is 31.11% up from last year.
  • Latest data reveals that Puma Biotechnology reported Non Operating Income of -$330,000 as of Q3 2025, which was up 29.94% from -$471,000 recorded in Q2 2025.
  • Puma Biotechnology's 5-year Non Operating Income high stood at $11.6 million for Q2 2021, and its period low was -$35.7 million during Q3 2021.
  • In the last 3 years, Puma Biotechnology's Non Operating Income had a median value of -$2.0 million in 2024 and averaged -$1.7 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first spiked by 409.72% in 2021, then tumbled by 539.73% in 2022.
  • Quarterly analysis of 5 years shows Puma Biotechnology's Non Operating Income stood at -$2.4 million in 2021, then tumbled by 539.73% to -$15.3 million in 2022, then surged by 86.99% to -$2.0 million in 2023, then surged by 43.48% to -$1.1 million in 2024, then skyrocketed by 77.57% to -$330,000 in 2025.
  • Its Non Operating Income stands at -$330,000 for Q3 2025, versus -$471,000 for Q2 2025 and -$717,000 for Q1 2025.